Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2022 Earnings Call Transcript

Sean Brynjelsen: Yes, it was relatively similar structure that payments are derisked over time, paid with success based milestones. It’s not going to be extremely expensive project. We think we’ve found a pretty good pathway to market that it can be done pretty inexpensively. So I think James mentioned, even including it into our R&D for this year, you’re only going to see a slight increase versus last year. But for competitive reasons, we’re not going into too much detail on the product at this time, but we hope to share more about it as we get closer to bring it to market.

James Kennedy: Very good. Okay. Thank you for taking my questions.

Sean Brynjelsen: Thank you.

Operator: And, thank you. And I would now like to turn the call back over to David Krempa for further remarks.

David Krempa: Thank you, operator. So we had two questions emailed into us I think we — Jim touched on both of them. The first was about ET-600. We talked about, it’s the same prescriber base. We don’t expect a significant increase in R&D related to the project. The second question was on the sales reps. And how quickly you expect to see a benefit? I think we already touched on that that we’re starting to see the early indications now. I think Carglumic Acid, we see the benefit much more quickly. It’s a little bit of an easier switch to convince the doctor to make. The ALKINDI SPRINKLE, you are actually doing some changing of prescribing habits. There’s a little more education that goes into it. So oftentimes you need to see a couple of visits with the doctor before they changed their habits.

So that one takes a little bit longer than Carglumic Acid switch, but we still expect to have a pretty good indication of the efficiency of the sales force in the next few months.

Sean Brynjelsen: Thanks David. And last, I’d just like to say, this is by far the most exciting year in our company’s history. I’d like to thank everybody who attended the call today. We are really looking forward to providing further updates as the year progresses. And we wouldn’t anticipate additional, let’s say, transactions, licensing deals, late stage products that will be part of that 10 that I mentioned.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.